ArticleCureus2026
Severe Immune-Mediated Thrombotic Thrombocytopenic Purpura With High-Titer ADAMTS13 Inhibitors: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening thrombotic microangiopathy caused by severe ADAMTS13 deficiency secondary to inhibitory autoantibodies. Prompt recognition and early initiation of treatment are essential to prevent irreversible organ damage and death. We report the case of a 46-year-old man who presented with constitutional symptoms, cutaneous purpura, severe thrombocytopenia, and microangiopathic hemolytic anemia. A PLASMIC score of 7 indicated a high probability of severe ADAMTS13 deficiency, which was confirmed by undetectable ADAMTS13 activity and high-titer inhibitory antibodies. The patient received therapeutic plasma exchange, corticosteroids, caplacizumab, and rituximab, resulting in rapid hematologic remission. An extensive diagnostic workup excluded alternative thrombotic microangiopathies. This case highlights the importance of early clinical recognition, systematic exclusion of alternative thrombotic microangiopathies, and prompt initiation of multimodal therapy in patients with suspected iTTP. It also illustrates the potential value of serial monitoring of ADAMTS13 activity and inhibitor titers as complementary biomarkers for assessing immunologic response and guiding therapeutic management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.